drugset
Drugs / SA14-14-2 vaccine
last change Oct 2011 re-read 3 minutes ago

SA14-14-2 vaccine

also known as CD.JEVAX · Japanese encephalitis live vaccine · LJEV

Vaccine

Developed for
Japanese encephalitis
Investigated by
PATH

Trials 1

today NCT00463476 · Ph 4
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 41 trial
Phase 4 NCT00463476 Jul → Nov 2007 Japanese encephalitis PATH Completed No outcome recorded
Comparator or background therapy1 trial
Phase 3 NCT01092507 Comparator Mar 2010 → Sep 2011 Japanese encephalitis Sanofi Pasteur, a Sanofi Company Completed Met primary

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as SA14-14-2 vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01092507 ↗
1

NCT00463476 ↗
Known as CD.JEVAX “Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)” NCT01092507 ↗
Known as Japanese encephalitis live vaccine “Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)” NCT01092507 ↗
Known as LJEV “Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)” NCT00463476 ↗
Modality Vaccine “live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV)” NCT00463476 ↗
Route Subcutaneous “Administered subcutaneously” NCT00463476 ↗